FDA panel recommends approval for Second Sight's 'bionic eye'

September 28, 2012 by MassDevice staff

FDA advisory panel recommends that the federal watchdog agency approve a humanitarian device exemption for Second Sight's Argus II "bionic eye" retinal implant.

Second Sight's Argus II retinal implant

An FDA advisory panel recommended approval for a "bionic eye" designed to restore sight for the blind.

The FDA's Ophthalmic Devices Panel voted 17-2 that the Argus II device's benefits outweigh any potential risks; 18-1 that a clinical trial demonstrated "a reasonable assurance of safety;" and was unanimously agreed that the proposed minimum age requirement of 25 years is appropriate.

The "bionic eye," which uses a head-worn camera to capture a scene and process it into electrical signals that are then sent to the cells in the eye, may pose long-term risks that increase over time, according to panel documents released ahead of the meeting. Nevertheless, the panel agreed that the federal watchdog agency ought to grant a humanitarian device exemption for the Argus II retinal prosthesis.

Sign up to get our free newsletters delivered straight to your inbox

The FDA is not obliged to abide by the panel's ruling, but usually follows its advisory boards' recommendations.

In a small study conducted in support of the FDA application, 30% of Argus II recipients required multiple revision surgeries to manage adverse events more than 2.5 years after the procedure. More than 40% experienced non-serious "fibrotic events," which include retinal detachment and retinal tears, and 10% suffered serious fibrotic events.

Comments